Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861136 | 0.85 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8326067 | 0.84 | MAPT (0.42) | L3MBTL1AKT1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6323174 | 0.83 | USP2 (0.36) | SMN1; SMN2USP2PIK3CAPIK3R1MTOR | |
| SCHEMBL8334943 | 0.82 | USP2 (0.36) | SMN1; SMN2USP2PIK3CAPIK3R1MTOR | |
| SCHEMBL8334947 | 0.82 | ALDH1A1 (0.32) | L3MBTL1ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL6318463 | 0.82 | USP2 (0.40) | SMN1; SMN2USP2PIK3CAPIK3R1MTOR | |
| SCHEMBL6265826 | 0.80 | L3MBTL1 (0.40) | L3MBTL1AKT1ALDH1A1KDM4ELMNA | |
| SCHEMBL860569 | 0.80 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1KDM4ESMN1; SMN2GLA | |
| SCHEMBL5847969 | 0.78 | L3MBTL1 (0.40) | L3MBTL1AKT1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4244018 | 0.77 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | L3MBTL1 4110/4885AKT1 948/4885ALDH1A1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.